A growing understanding of purinergic signaling is reshaping how scientists view osteoarthritis (OA), revealing an intricate communication network that influences joint inflammation, cartilage degeneration, bone remodeling, and chronic pain. A new review article highlights how disruptions in this signaling system may play a central role in disease progression while identifying promising opportunities for more targeted therapies that could slow or modify the course of OA rather than simply relieve symptoms.
Osteoarthritis is the most common form of arthritis and a leading cause of pain and disability worldwide. Once regarded primarily as a consequence of mechanical wear and tear, it is now understood to involve complex biological processes that affect the entire joint. The review explains that purinergic receptors, which respond to molecules released by damaged or stressed cells, help regulate normal joint function but become dysregulated during osteoarthritis, driving inflammation and tissue damage.
The article describes two major groups of receptors with contrasting roles. P2 receptors respond to extracellular nucleotides such as ATP and are associated with inflammatory signaling, cartilage breakdown, and pain when excessively activated. In contrast, P1 receptors, which respond to adenosine, generally support protective processes that help maintain cartilage integrity, reduce inflammation, and promote tissue repair. The balance between these signaling pathways appears to be essential for preserving healthy joint function.
The review outlines how specific receptor subtypes influence different aspects of osteoarthritis. Some contribute to inflammatory pathways that damage cartilage and alter the underlying bone, while others are closely linked to the development of persistent pain. At the same time, protective receptors may enhance autophagy, improve mitochondrial function, reduce oxidative stress, and help preserve the extracellular matrix that provides cartilage with its strength and resilience.
The authors also discuss the therapeutic potential of selectively targeting these signaling pathways. Strategies aimed at blocking harmful P2 receptor activity while enhancing beneficial P1 receptor signaling could provide a more comprehensive approach to managing osteoarthritis by addressing both structural damage and pain. Although several candidate compounds are being explored, further development is needed to improve receptor selectivity, minimize unwanted effects, and optimize delivery to affected joints.
